AkzoNobel, Itaconix to develop bio-based chelates for detergents

AkzoNobel’s speciality chemicals business and Itaconix PLC have signed an application agreement to evaluate and develop innovative bio-based chelates for use in the consumer and industrial detergents and cleaners markets. It is the second partnership stemming from a joint development agreement signed by the companies earlier this year to develop and commercialize sustainable products made from renewable feedstocks using Itaconix technology. Read more


INTEGRA Biosciences AG is making multichannel pipetting quicker and easier than ever before. The company’s extensive range of manual and electronic handheld pipettes – combined with the revolutionary GripTips system – is helping take the ‘pain’ out of multichannel pipetting, boosting productivity and ensuring happy, healthy staff. The difficulties associated with using handheld multichannel pipettes are familiar to every lab scientist; tips need ‘hammering’ on to ensure they are picked up, but this still doesn’t always ensure correct tip alignment. Read more


AkzoNobel NV has opened a speciality coatings facility in Dongguan, China, committed to producing aerospace coatings for the North and South Asian aviation market. This new facility will offer improved and faster service to existing, as well as new customers, in this rapidly-growing market. The new manufacturing site joins existing facilities located in Leicester (UK), Moscow (RU), Sao Paulo (BR), in addition to the main production centres in Waukegan (US), and Sassenheim (NL). Read more


Novartis International AG has appointed Dr Vasant Narasimhan, currently global head (drug development) and chief medical officer as its new chief executive officer (CEO), effective from 1 February 2018. He succeeds Joseph Jimenez, who has informed the board of directors of his desire to step down as CEO in 2018, after eight years in the position. Narasimhan is a member of the executive committee and joined Novartis in 2005. He has held numerous leadership positions across Novartis in commercial. Read more